Elevated expression of Ets2 or distinct portions of Ets2 can reverse Ras-mediated cellular transformation - PubMed (original) (raw)
. 1998 Jul 24;273(30):18871-80.
doi: 10.1074/jbc.273.30.18871.
Affiliations
- PMID: 9668063
- DOI: 10.1074/jbc.273.30.18871
Free article
Elevated expression of Ets2 or distinct portions of Ets2 can reverse Ras-mediated cellular transformation
G Foos et al. J Biol Chem. 1998.
Free article
Abstract
Ets transcription factors are important downstream targets of oncogenic Ras. The transcriptional activity of several Ets family members is regulated by Ras, and interfering with Ets-dependent transcription by expression of just the Ets2 DNA binding domain can inhibit or reverse Ras-mediated cellular transformation. To better understand the role of Ets proteins in Ras transformation, we have now analyzed the effects of stably expressing a variety of Ets2 constructs in Ras-transformed NIH3T3 (DT) cells. Expression of only the Ets2 transactivation domains, which also inhibits Ras or Neu/ErbB-2-mediated activation of Ets-dependent transcription, strongly inhibited anchorage-independent growth, but did not revert the transformed DT cell morphology. Unexpectedly, high expression of full-length Ets2, a transcriptional activator, broadly reversed the transformed properties of DT cells, including anchorage-independent growth, transformed morphology, and tumorigenicity, but did not impair attached cell growth. Increasing full-length Ets2 transcriptional activity by fusing it to the VP16 transactivation domain enhanced its ability to reverse DT cell transformation. Mutational analysis revealed that the mitogen-activated protein kinase phosphorylation site required for Ras-mediated activation, Ets2(T72), was not essential for Ets2 reversion activity. The distinct reversion activities of the highly expressed Ets2 transactivation domains or full-length Ets2, along with the specific reversion activity by Ets2 constructs that either inhibit or activate Ets-dependent transcription, suggests multiple roles for Ets factors in cellular transformation. These results indicate that several distinct approaches for modulating Ets activity may be useful for intervention in human cancers.
Similar articles
- Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness.
Foos G, Hauser CA. Foos G, et al. Oncogene. 2000 Nov 16;19(48):5507-16. doi: 10.1038/sj.onc.1203946. Oncogene. 2000. PMID: 11114728 - Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation.
Galang CK, García-Ramírez J, Solski PA, Westwick JK, Der CJ, Neznanov NN, Oshima RG, Hauser CA. Galang CK, et al. J Biol Chem. 1996 Apr 5;271(14):7992-8. doi: 10.1074/jbc.271.14.7992. J Biol Chem. 1996. PMID: 8626480 - Ets2 is not required for Ras or Neu/ErbB-2 mediated cellular transformation in vitro.
Hevér A, Oshima RG, Hauser CA. Hevér A, et al. Exp Cell Res. 2003 Oct 15;290(1):132-43. doi: 10.1016/s0014-4827(03)00315-x. Exp Cell Res. 2003. PMID: 14516794 - Ets transcription factors and targets in osteogenesis.
Raouf A, Seth A. Raouf A, et al. Oncogene. 2000 Dec 18;19(55):6455-63. doi: 10.1038/sj.onc.1204037. Oncogene. 2000. PMID: 11175361 Review. - Signal transduction and the Ets family of transcription factors.
Yordy JS, Muise-Helmericks RC. Yordy JS, et al. Oncogene. 2000 Dec 18;19(55):6503-13. doi: 10.1038/sj.onc.1204036. Oncogene. 2000. PMID: 11175366 Review.
Cited by
- CIP/KIP and INK4 families as hostages of oncogenic signaling.
Csergeová L, Krbušek D, Janoštiak R. Csergeová L, et al. Cell Div. 2024 Apr 1;19(1):11. doi: 10.1186/s13008-024-00115-z. Cell Div. 2024. PMID: 38561743 Free PMC article. Review. - A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.
Hong MJ, Lee SY, Choi JE, Jin CC, Kang HJ, Baek SA, Lee SY, Shin KM, Jeong JY, Lee WK, Yoo SS, Lee J, Cha SI, Kim CH, Son JW, Park JY. Hong MJ, et al. Oncotarget. 2016 Mar 29;7(13):15948-58. doi: 10.18632/oncotarget.7433. Oncotarget. 2016. PMID: 26893365 Free PMC article. - Intrinsically active variants of Erk oncogenically transform cells and disclose unexpected autophosphorylation capability that is independent of TEY phosphorylation.
Smorodinsky-Atias K, Goshen-Lago T, Goldberg-Carp A, Melamed D, Shir A, Mooshayef N, Beenstock J, Karamansha Y, Darlyuk-Saadon I, Livnah O, Ahn NG, Admon A, Engelberg D. Smorodinsky-Atias K, et al. Mol Biol Cell. 2016 Mar 15;27(6):1026-39. doi: 10.1091/mbc.E15-07-0521. Epub 2015 Dec 10. Mol Biol Cell. 2016. PMID: 26658610 Free PMC article. - ETS family transcriptional regulators drive chromatin dynamics and malignancy in squamous cell carcinomas.
Yang H, Schramek D, Adam RC, Keyes BE, Wang P, Zheng D, Fuchs E. Yang H, et al. Elife. 2015 Nov 21;4:e10870. doi: 10.7554/eLife.10870. Elife. 2015. PMID: 26590320 Free PMC article. - Ets-1 global gene expression profile reveals associations with metabolism and oxidative stress in ovarian and breast cancers.
Verschoor ML, Verschoor CP, Singh G. Verschoor ML, et al. Cancer Metab. 2013 Jul 25;1(1):17. doi: 10.1186/2049-3002-1-17. Cancer Metab. 2013. PMID: 24280356 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous